Top

Published in:

01-10-2014 | What's New in Intensive Care

What is new in the use of aminoglycosides in critically ill patients?

Authors: Dimitrios K. Matthaiou, Jan De Waele, George Dimopoulos

Published in: Intensive Care Medicine | Issue 10/2014

Excerpt

When aminoglycosides are used in critically ill patients, it is crucial that their efficacy is maximised. Aminoglycosides are concentration-dependent antibiotics, and the peak concentration over minimum inhibitory concentration (MIC) is the relevant pharmacokinetics/pharmacodynamics (PK/PD) parameter. Studies have shown that aminoglycosides have their maximal effect at C _max/MIC ratio of 8–10. This means that therapeutic drug monitoring (TDM) for efficacy, i.e. monitoring peak levels, may be helpful to guide therapy [1]. …

De Waele J, De Neve N (2013) Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring. Minerva Anestesiologica [Epub ahead of print]

Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851 (quiz 859)PubMedCrossRef

Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F (2010) Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14:R53PubMedCrossRefPubMedCentral

Goncalves-Pereira J, Martins A, Povoa P (2010) Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect 16:1258–1263PubMedCrossRef

Tamma PD, Cosgrove SE, Maragakis LL (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25:450–470PubMedCrossRefPubMedCentral

de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R (2014) Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 40(7):998–1005. doi:10.1007/s00134-014-3276-x PubMedCrossRef

Zazo H, Martin-Suarez A, Lanao JM (2013) Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Int J Antimicrob Agents 42:155–160PubMedCrossRef

Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D (2013) Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med 39:1247–1252PubMedCrossRef

D’Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI (2012) An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol 13:14PubMedCrossRefPubMedCentral

10.

Petejova N, Zahalkova J, Duricova J, Kacirova I, Brozmanova H, Urbanek K, Grundmann M, Martinek A (2012) Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother 24:107–112PubMedCrossRef

11.

Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Gennaro P, Raponi G, Vitale M, Pietropaoli P, Antonelli M (2013) Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17:R174PubMedCrossRefPubMedCentral

12.

Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78:443–448PubMedCrossRef

13.

Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, Valakis C, Maltezou HC (2014) Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 20:O117–O123PubMedCrossRef

14.

Ehrmann S, Roche-Campo F, Sferrazza Papa GF, Isabey D, Brochard L, Apiou-Sbirlea G (2013) Aerosol therapy during mechanical ventilation: an international survey. Intensive Care Med 39:1048–1056PubMedCrossRef

15.

Daneman N, Sarwar S, Fowler RA, Cuthbertson BH (2013) Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13:328–341PubMedCrossRef

Title: What is new in the use of aminoglycosides in critically ill patients?
Authors: Dimitrios K. Matthaiou
Jan De Waele
George Dimopoulos
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 10/2014
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-014-3376-7

At a glance: The STEP trials

Springer Medicine

What is new in the use of aminoglycosides in critically ill patients?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2014

Has survival increased in cancer patients admitted to the ICU? No

Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: reply to Roux and Ricard

Has survival increased in cancer patients admitted to the ICU? We are not sure

Thyrotoxic cardiomyopathy with recurrent ventricular fibrillation and multi-organ failure

Adverse events of haloperidol for the treatment of delirium in critically ill children

An increased alveolar CD4+ CD25+ Foxp3+ T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality: response to comment by Singer and D’Alessio